GUIDANCE ON THE USE OF AZTREONAM in ADULTS




Key Points about Aztreonam:

- Does NOT provide the same level of antibacterial cover as Gentamicin
- Provides only gram negative bacilli cover
- If stock not available, please see <u>alternatives guidance</u>

- Does NOT provide anaerobic or gram positive cover
- Does NOT provide cover for ESBL producing gram negative bacteria

Indications for Aztreonam:

- As an alternative to gentamicin for patients with reduced renal function or patients who have had 96hours of gentamicin and still require IV therapy see flow chart below
- Follow separate guidance documents for Cystic Fibrosis, Pregnancy, Neutropenic Sepsis, Endocarditis, Surgical Prophylaxis, Renal Unit Inpatients or patients on dialysis



Severe Systemic Infection	Antibiotics	Penicillin allergy	Oral Step Down
		*History of anaphylaxis or angiodema with penicillin replace Aztreonam with Ciprofloxacin	(or as per sensitivities)
Intrabdominal Sepsis/	IV Amoxicillin/Metronidazole/Aztreonam	IV Vancomycin/Metronidazole/*Aztreonam	PO Co-trimoxazole + Metronidazole
Sepsis Unknown Source	(add Flucloxacillin if staphylococcal infection suspected)		
Complicated UTI/	IV Amoxicillin/Aztreonam	IV Vancomycin/*Aztreonam	PO Co-trimoxazole
Urosepsis/ Pyelonephritis			
Aspiration Pneumonia	IV Amoxicillin/Aztreonam	IV/PO Co-trimoxazole	PO Co-trimoxazole
Hospital Acquired Pneumonia	IV Amoxicillin/Aztreonam	IV/PO Co-trimoxazole	PO Co-trimoxazole

AZTREONAM DOSING:

REMEMBER LAST GENTAMICIN DOSE PROVIDES GRAM NEGATIVE COVER UNTIL END OF DOSING INTERVAL as read from nomogram i.e. 24, 36 or 48 hours. PRESCRIBE AZTREONAM TO START AT THE END OF THAT INTERVAL.

eGFR ≥30 2g tds

eGFR <30 but >10 2g loading dose then 1g tds eGFR<10 2g loading dose then 500mg tds

CO-TRIMOXAZOLE DOSING:

Standard dose 960mg bd eGFR <30 and >15 480mg bd

if eGFR <15: alternatives options but beware of ↑CDI risk

- co-amoxiclay (no additional metronidazole required)
- ciprofloxacin (if penicillin allergic)

Developed by: AMG Approved: Feb 2017 Updated: June 2022 Amended: April 2024

Review: June 2025